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Early Tumor Response to Intraarterial or Intravenous
Administration of Carboplatin to Treat Naturally Occurring Lower
Urinary Tract Carcinoma in Dogs
W.T.N. Culp, C. Weisse, A.C. Berent, J.A. Reetz, E.L. Krick, D.E. Jackson, P.H. Kass,
C.A. Clifford, and K.U. Sorenmo
Background: Survival times and tumor responses associated with malignant neoplasia of the lower urinary tract are poor
despite the vast array of current treatments. Therefore, the evaluation of alternative treatments, such as intraarterial adminis-
tration of chemotherapy (IAC) should be considered.
Objective: To describe a technique for superselective catheterization for IAC and to evaluate initial tumor response by
ultrasonography after both IAC and intravenous administration of chemotherapy (IVC).
Animals: Client-owned dogs with lower urinary tract neoplasia treated with either IVC (n = 15) or IAC (n = 11).
Methods: Retrospective study. An arterial approach via the carotid or femoral artery was utilized to obtain superselective
access and administer chemotherapy in the IAC cases. Medical record review was performed, data were recorded, and
recorded variables were evaluated statistically.
Results: Intraarterial chemotherapy was successfully administered in all cases. There was a significantly greater decrease
in longest unidimensional measurement in the IAC group as compared to the IVC group (P = .013). The IAC group was also
significantly more likely to have a tumor response as assessed by modified RECIST guidelines (P = .049). Dogs in the IAC
group were significantly less likely to develop anemia (P = .001), lethargy (P = .010) and anorexia (P = .024).
Conclusion and Clinical Importance: This study demonstrated the feasibility and efficacy of performing IAC for lower uri-
nary tract neoplasia. Further investigation is necessary as the follow-up time was short and the impact on long-term outcome
and survival was not determined.
Key words: Chemotherapy; Transitional cell carcinoma.
Malignant neoplasia of the lower urinary tract ofdogs generally carries a poor prognosis. Carcino-
mas are the most common neoplasm affecting the uri-
nary bladder, urethra and prostate of dogs, and the
majority of these tumors are urothelial in origin, with
the predominant subtype being transitional cell carcino-
mas (TCC).1,2 Traditional treatments include surgery,
nonsteroidal anti-inflammatory drugs, chemotherapy,
radiotherapy, or a combination of these modalities.2–8
The results from such treatments have been mixed. In
most practices, chemotherapy administered IV in
conjunction with an oral nonsteroidal anti-inflammatory
drug (NSAID) is the pursued treatment. Mitoxantrone,
cisplatin, carboplatin, chlorambucil, doxorubicin, acti-
nomycin D, and vinblastine have antitumor activity
against urinary bladder and urethral TCC; however,
tumor responses are typically incomplete and short-last-
ing. Median survival times have differed depending on
the protocol utilized but are generally <1 year.3,4,7,9–15
Nonsteroidal anti-inflammatory drugs administered
either alone or in combination with chemotherapy are
commonly used in the treatment of TCC.16–18 Tumor
regressions occurred in 6 of 34 dogs treated with piroxi-
cam as a single agent, and 2 of these cases had complete
and durable remissions while on treatment.16 The
response to NSAIDs has been confirmed by several fol-
low-up studies.4,7,17,19 As only complete responses
(CRs) are likely to significantly prolong remission and
survival in cancer patients, the activity of NSAIDs in
canine TCC has received significant attention.
An alternative to the traditional intravenous adminis-
tration of chemotherapy is the intraarterial administra-
tion of chemotherapy. In humans, the use of
intraarterial chemotherapy (IAC) is expanding. In these
cases, arterial access is obtained and fluoroscopic guid-
ance is utilized to achieve superselective catheter place-
ment within the arterial supply of a tumor. The goal of
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IAC delivery is to increase the local (and subsequently
intratumoral) concentration of chemotherapy, decrease
systemic adverse effects, and potentially generate a
greater tumor response.20
The use of IAC for the treatment of urinary bladder
TCC has been described in 2 dogs.21 In those dogs,
arterial access was obtained via the carotid artery and
IAC (cisplatin) was administered at the level of the
external iliac arteries; radiotherapy was also adminis-
tered to potentially generate an improved response with
the combined therapy. In those dogs, minimal adverse
effects were noted and the procedure was performed
without incident.21 Some of the dogs in the IAC treat-
ment group in the current report were also included in
an abstract describing the technique and repeatability of
superselective IAC in dogs with urothelial tumors.22 In
those cases, 22 dogs received up to 6 treatments each,
often in terminal arteries, and complications were
uncommon and typically minor.22
As survival times and tumor responses remain poor
despite the vast array of surgery, radiotherapy and che-
motherapy protocols utilized in the treatment of neopla-
sia affecting the lower urinary tract, evaluation of
alternative treatments is necessary. The primary goal of
this study was to describe a technique for superselective
catheterization of the arterial blood supply to the uri-
nary bladder, urethra, and prostate for the specific pur-
pose of intraarterial administration of chemotherapy
and NSAIDs. A secondary goal was to compare initial
tumor response (before treatment and subsequent ultra-
sonography evaluation) after IA administration of car-
boplatin in 1 group of dogs to initial tumor response
after IVC in a different cohort of dogs. Initial tumor
response was defined as the change in tumor size from
the ultrasound evaluation before treatment to the ultra-
sound evaluation after treatment. We hypothesized that
a technique of superselection of arteries supplying the
lower urinary tract of dogs would be feasible, safe, and
repeatable, and there would be a greater decrease in
tumor size after IAC than IVC utilizing carboplatin.
Materials and Methods
Criteria for Selection of Cases
A retrospective, multi-institutional study was performed. The
databases of the Interventional Radiology and Oncology clinics at
the University of Pennsylvania School of Veterinary Medicine
(2007–2009) and the Animal Medical Center Interventional Radi-
ology Service (2009) were searched for dogs with neoplasia (carci-
noma) of the urinary bladder, urethra, or prostate that were
treated by IAC or IVC administration. Dogs were included in the
IAC group if a cytologic or histologic diagnosis of carcinoma was
obtained, and carboplatin and an NSAID were administered via
artery by a single operator. Dogs were included in the IVC group
if a cytologic or histologic diagnosis of carcinoma was obtained,
and a protocol of intravenous carboplatin and an oral NSAID
was administered under the supervision of a board-certified veteri-
nary oncologist during the same time period as the IAC group;
dogs receiving other chemotherapy drugs were excluded. No dog
in either group had received previous treatment with an NSAID,
chemotherapy, or radiation therapy.
Procedures
Medical record review was performed and data recorded from
the medical record included: signalment (age, breed, and sex),
weight, diagnostic imaging findings (radiography and ultrasonog-
raphy), and IAC procedural findings. Additionally, the adverse
events/complications were noted after each chemotherapy treat-
ment and recorded according to published VCOG-CTCAE guide-
lines.23
Vascular Selection: Carotid Artery. All dogs were placed in dor-
sal recumbency and the ventral and lateral cervical neck regions
were clipped and prepared with sterile technique. A 2–4 cm inci-
sion was made between the trachea and jugular vein on the left or
right side. The subcutaneous tissues were bluntly and sharply dis-
sected until the carotid arterial pulse could be palpated. The fascia
surrounding the carotid sheath was gently dissected to allow clear
visualization and isolation of the carotid artery. Two lengths of 3-
0 polydioxanonea suture were placed around the exposed region of
the carotid artery. The cranial polydioxanone suture was ligated
around the carotid artery. An 18-gauge over-the-needle catheterb
was introduced into the carotid artery and the needle was
removed. An 0.035-inch hydrophilic guide wirec was introduced
into the catheter and subsequently into the carotid artery. The
catheter was removed over the guide wire. A 4-6 Fr vascular
access sheath and dilatord were introduced into the carotid artery
over the guide wire, and the caudal polydioxanone suture was left
in place loosely. The sheath was sutured to the skin and the dila-
tor was removed over the guide wire.
The fluoroscopy unit was then positioned over the dog. A 4 Fr
Berenstein cathetere was introduced into the vascular access sheath
over the guide wire and the guide wire-catheter combination was
passed from the carotid artery into the thoracic aorta and further
into the abdominal aorta to the level of the caudal aorta (Fig 1).
The guide wire was then removed from the vascular access sheath.
A 50% saline/50% contrastf mixture was drawn into a syringe and
attached to the Berenstein catheter, and approximately 5 mL was
injected under fluoroscopic guidance to delineate the vascular
anatomy of the terminal aorta (Fig 1).
Vascular Selection: Femoral Artery. All dogs were placed in
dorsal recumbency and the inguinal region was clipped and pre-
pared with sterile technique. The right or left femoral artery was
digitally palpated through the skin, and a 2 cm incision over the
femoral artery was made. The fascia surrounding the femoral
artery was dissected allowing clear visualization of the femoral
artery. Two lengths of 3-0 polydioxanonea suture were placed
around the exposed region of the femoral artery. The distal polydi-
oxanone suture was ligated around the femoral artery. An 18-
gauge over-the-needle catheter was introduced into the femoral
artery and the needle was removed. An 0.035-inch hydrophilic
guide wire was introduced into the catheter and subsequently into
the femoral artery. The catheter was removed over the guide wire.
A 4-6 Fr vascular access sheath and dilator were introduced into
the femoral artery over the guide wire and the proximal polydioxa-
none suture was left in place loosely. The sheath was sutured to
the skin and the dilator was removed over the guide wire.
The fluoroscopy unit was then positioned over the caudal abdo-
men of the patient. The guide wire was passed from the femoral
artery and into the ipsilateral external iliac artery. A 4 Fr Cobrag
catheter was then placed into the vascular access sheath over the
guide wire. Using the guide wire and Cobra catheter combination,
the contralateral external iliac artery was selected. The Cobra cath-
eter was then removed over the wire and replaced with a 4Fr
reverse curve catheterh . The catheters were then manipulated into
the terminal aorta at the level of the internal iliac arteries. The
guide wire was then removed and a 50% saline/50% contrast mix-
ture was drawn into a syringe that was attached to the catheter
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and approximately 5 mL was injected under fluoroscopic guidance
to delineate the vascular anatomy of the terminal aorta.
Intraarterial Chemotherapy Administration. Superselection of the
terminal arteries was attempted in all cases. To perform superse-
lection, a microwire (0.014-inch)i and microcatheter (1.8–2.4 Fr)j
combination was used to access the internal iliac artery and subse-
quently the internal pudendal artery (Fig 1). The microwire was
then removed, and the patient was moved into lateral recumbency
to allow for better visualization of the terminal arteries. Once in
lateral recumbency, an injection of 100% contrast was performed
to delineate the arterial supply to the tumor and the terminal
arteries. The microwire was reintroduced into the microcatheter
and the combination was utilized to select the most terminal artery
(prostatic, vaginal, or caudal vesical).
Before chemotherapy administration, a separate sterile surgical
table was established, and all individuals in the catheterization lab-
oratory donned appropriate protective gear including goggles and
powder-free gloves. Chemotherapy (carboplatin) and meloxicam
were placed onto the surgical table with sterile technique. The sys-
temic dose of carboplatin was utilized in all cases; 250 mg/m2 was
administered at the 1st treatment, and if this was tolerated, the
dose was increased to 275 mg/m2 at the 2nd dose. The dose of me-
loxicam administered intraarterially was between 0.1 and 0.2 mg/
kg; the lower dose was chosen in dogs with a previous history of
gastrointestinal upset or poor tolerance of NSAIDs. Undiluted
chemotherapy was mixed with contrast 1:1 to allow for visualiza-
tion during administration to limit reflux of chemotherapy into
more proximal arteries; half of the chemotherapy administration
was performed via 1 mL syringes attached to the microcatheter
on 1 side. After chemotherapy administration, the microcatheter
was flushed with saline and then half of the meloxicam dose was
administered mixed 1:1 with contrast as well. Once injection
was complete, the microcatheter was flushed with saline and a
repeat arteriogram was performed to confirm blood flow to the
area and document any evidence of thrombosis or extravasation.
After the treatment of 1 side of the lower urinary tract with half
of the chemotherapy and meloxicam dose, the patient was moved
into dorsal recumbency again. The Cobra catheter and microcathe-
ter combination were withdrawn slowly to the level of the internal
iliac arteries and vascular selection was performed on the contra-
lateral side allowing for administration of the remaining half of
the chemotherapy and meloxicam dose in the same manner as
described above.
After completion of IAC administration, the instrumentation
was removed, and the artery was ligated. The subcutaneous tissue
and skin were closed with 3-0 poliglecapronek in 2 layers. In total,
2 full doses of IAC were administered 3 weeks apart, and abdomi-
nal ultrasonographic evaluation of the tumor was performed after
the first 2 treatments. The total dose of contrast administered did
not exceed 2 mL/kg in any dog.
Imaging, Tumor Measurement, and Endpoints for Compari-
sons. An abdominal ultrasonographic examination was performed
before treatment in all dogs (IAC and IVC groups) and after 2
treatments (IAC group) or 2–3 treatments (IVC group) had been
administered. The response comparison endpoint between the 2
treatment groups was the after treatment ultrasound. For this
study, a single board-certified radiologist retrospectively reviewed
all ultrasonographic examination images and recorded the follow-
ing tumor parameters on the before treatment and first after treat-
ment ultrasonographic examination: the longest diameter length,
width, and height, from which the estimated tumor volume was
ultimately calculated. When archived ultrasound images only
included 1 imaging plane (ie, sagittal plane), bidimensional mea-
surements were obtained but estimated tumor volume could not
be calculated. The percentage change in tumor length, width,
height, and volume were calculated. To determine tumor response,
a modification of the RECIST guidelines was utilized based upon
the longest unidimensional ultrasonography measurement (rather
than the originally described computed tomography or caliper
measurements)24; briefly, when comparing the first to second ultra-
sonography assessment, a CR was considered the disappearance of
the lesion, a PR was considered at least a 30% decrease in the tar-
A B
C D
Fig 1. Fluoroscopic images during an intraarterial chemotherapy procedure for the treatment of a prostatic carcinoma. (A) A contrast
injection with digital subtraction has been performed at the level of the caudal aorta, and the arteries of the aortic trifurcation can be visu-
alized. (B) The Berenstein catheter has been advanced into the internal iliac artery, and the internal pudendal artery can now be visualized
during this subtracted contrast injection. (C) The dog has been repositioned into lateral recumbency, and the Berenstein catheter (*) can be
visualized at the origin of the internal pudendal artery. (D) The arteries that are selected during superselection of the prostatic artery can
be visualized in this subtracted image.
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get lesion diameter, progressive disease (PD) was considered at
least a 20% increase in the target lesion diameter, and stable dis-
ease (SD) was considered a lesion that demonstrated neither suffi-
cient regression to be considered a PR nor sufficient growth to be
considered PD. A specific protocol to fill the bladder with a con-
sistent amount of fluid before ultrasound was not followed.
Statistical Analysis
The changes in length, height, width, and volume and the per-
centage change in length, height, width, and volume were com-
pared between the IAC and the IVC groups using an exact
Wilcoxon-Mann–Whitney test. Additionally, the change in the lon-
gest unidimensional measurement and the percentage change in
the longest unidimensional measurement were compared between
the IAC and the IVC groups, as were the modified RECIST
responses in each group, using an exact Wilcoxon-Mann–Whitney
test. Before and after treatment, paired data were analyzed with
an exact Wilcoxon signed rank test. Dichotomous variables were
compared between the IAC and the IVC groups using Fisher’s
exact test. P-values ≤.05 were considered statistically significant.
Results
Intraarterial Chemotherapy Subgroup
Eleven dogs met inclusion criteria in the IAC cohort.
The median age of the dogs receiving IAC was 11 years
(range, 6.5–13 years). Breeds represented included
Bassett Hound (1), Bearded Collie (1), Bichon Frise (1),
Lhasa Apso (1), Pembroke Welsh Corgi (1), Samoyed
(1), Scottish Terrier (1), Shih Tzu (1), and Yorkshire
Terrier (1); additionally, 2 dogs were considered mixed
breed. There were 8 female spayed and 3 male castrated
dogs included in this group. The median weight of the
dogs enrolled in the group was 16 kg (range,
5.8–31 kg).
Thoracic radiography (3-view) was performed prior
to IAC administration in all cases. Eight dogs were
noted to have normal thoracic radiographs. Abnormali-
ties on thoracic radiographs included suspected pulmo-
nary parenchymal metastatic disease (n = 3), mildly
enlarged heart (2), suspected rib metastasis (1), and sus-
pected dorsal spinous process metastasis (1). Abdominal
ultrasonography results were available for all dogs. A
mass or masses was noted in the bladder/urethra
(n = 8) or prostate (3) in all dogs. A diagnosis was
obtained in all cases and included transitional cell carci-
noma (n = 8) and prostatic carcinoma (3).
The carotid artery was utilized for vascular access in
9 dogs, and the femoral artery was used for access in 2
dogs. Anesthesia and procedural times were available in
8 cases (17/22) procedures. The median total anesthesia
time during the IAC administration was 150 minutes
(range, 80–220 minutes) and the median IAC proce-
dural time was 70 minutes (range, 35–135 minutes). The
intraprocedural complications included hemorrhage
from a secondary peripheral arterial line (n = 1) and a
unilateral delivery of the full-dose chemotherapy (1).
No bleeding complications at the vascular access site
were noted, and all cases were considered technical suc-
cesses in that catheters were able to be positioned in the
blood vessel of choice and chemotherapy was adminis-
tered successfully. After procedure complications
included mild lameness in 2 dogs that had undergone
femoral arterial access. One dog that required bilateral
carotid artery ligation had temporary blindness and dis-
orientation, likely secondary to an ischemic event. The
adverse events associated with IAC administration
included 8 neutropenic episodes (7 grade 1 and 1 grade
2) and 2 episodes of diarrhea (grade 1).
All dogs had ultrasonographic evaluation of the
tumor before treatment and again after 2 treatments
(approximately 3 weeks after the second treatment).
The tumor measurements and percentage changes are
recorded in Table 1. When utilizing the modified RE-
CIST guidelines described in this study, 4 dogs had a
PR, and 7 dogs demonstrated SD when comparing the
first and second ultrasonography assessments. No dogs
had PD.
There was a significant decrease in tumor length
(P = .002), width (P = .031), and height (P = .015)
when comparing the before treatment ultrasonography
measurements to the after treatment ultrasonography
measurements. Additionally, there was a significant dif-
ference when comparing the before treatment longest
unidimensional measurement to the after treatment lon-
gest unidimensional measurement (P = .001).
Intravenous Chemotherapy Subgroup
Fifteen dogs met inclusion criteria in the IVC cohort.
The median age of the dogs receiving IVC was 11 years
(range, 8.5–13.5 years). Breeds represented included
Beagle (n = 2), Labrador retriever (1), Lhasa Apso (1),
Maltese (1), Rat Terrier (1), Scottish Terrier (1), Soft-
coated Wheaten Terrier (1), and West Highland White
Terrier (1); 6 dogs were considered mixed breed. There
were 7 female spayed, 7 male castrated dogs and 1
intact male dog included in this group. The median
weight of the dogs enrolled in the group was 15.6 kg
(range, 8.6–41.9 kg).
Thoracic radiography (3-view) was performed before
IVC administration in all cases. Fourteen dogs were
noted to have no abnormal findings on thoracic radio-
graphs. Suspected pulmonary metastasis was noted in 1
dog. Abdominal ultrasonography examination results
were available in all dogs. One or more masses were
noted in the bladder/urethra (n = 14) or prostate (1) in
all dogs. A diagnosis was confirmed as TCC in all 15
cases.
A total of 44 IVC administrations were performed in
these 15 dogs; 14 dogs received 3 treatments, and 1 dog
received 2 treatments. The dose of carboplatin varied
between 250 and 300 mg/m2. Ten dogs received piroxi-
cam (0.2–0.3 mg/kg, PO, q24 hour), 2 dogs received
firocoxib (4.7–4.9 mg/kg, PO, q24 hour), 1 dog received
carprofen (2.5 mg/kg, PO, q12 hour), 1 dog received
deracoxib (1.8 mg/kg, PO q24 hour), and 1 dog
received meloxicam (0.1 mg/kg, PO, q24 hour). The
adverse events associated with IVC administration
included anemia after 18 individual treatments (16
grade 1, 2 grade 2), neutropenia after 22 treatments (13
grade 1, 7 grade 2, 1 grade 3, 1 grade 4), thrombocyto-
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penia after 6 treatments (3 grade 1, 1 grade 2, 2 grade
3), lethargy after 10 treatments (10 grade 1), anorexia
after 10 treatments (6 grade 1, 4 grade 2), and diarrhea
after 8 treatments (6 grade 1, 2 grade 2).
All 15 dogs had 2 ultrasonography examinations of
the tumor with the first occurring before IVC treatment,
and the second occurring after 3 treatments in 14 dogs
and after 2 treatments in 1 dog (approximately 3 weeks
after the last treatment). The tumor measurements and
percentage changes can be found in Table 1. When uti-
lizing the modified RECIST guidelines described in this
study, 2 dogs demonstrated a PR, 9 dogs demonstrated
SD, and 4 dogs demonstrated PD when comparing the
first and second ultrasonography assessments.
There was no significant decrease in tumor length
(P = .525), width (P = .496), and height (P = .867)
when comparing the ultrasonography measurements
before and after treatment. Additionally, there was not
a significant difference when comparing the longest uni-
dimensional measurement before and after treatment
(P = .52).
Comparison Between Intraarterial and Intravenous
Groups
There was no significant difference between the IAC
and IVC groups for age (P = .89), weight (P = .34),
and sex (P = .82). The P values for comparison between
the IAC and IVC groups can be found in Table 1.
There was no significant difference in the before treat-
ment height (P = .07), length (P = .78), width (P = .31),
volume (P = .18), and longest unidimensional measure-
ment (P = .64) when comparing the IAC and IVC
groups. There was a significantly greater decrease in
tumor length, length percentage, width percentage, lon-
gest unidimensional measurement, and longest unidi-
mensional measurement percentage after treatment in
the IAC group as compared to the IVC group. The
IAC group was significantly more likely to have a
tumor response as assessed by modified RECIST guide-
lines when compared to the IVC group (P = .049); eg, 4
of 11 (36%) in the IAC group had a PR, compared to
2 of 15 (13%) in the IVC group.
The development of adverse events was compared
between the 2 groups. There was no significant differ-
ence in the development of neutropenia (P = .109),
thrombocytopenia (P = .053), diarrhea (P = .356), and
vomiting (P = .491). Dogs in the IAC group were sig-
nificantly less likely to develop anemia (P = .001), leth-
argy (P = .010), and anorexia (P = .024).
Discussion
The results of this study demonstrate that IAC for
the treatment of lower urinary tract neoplasia can be
performed successfully and with minimal complications.
Additionally, early tumor response is encouraging as
the IAC group demonstrated a significantly greater
decrease in tumor length, length and width percentage,
longest unidimensional measurement, and longest unidi-
mensional measurement percentage as compared to the
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IVC group when using carboplatin and NSAID chemo-
therapy protocols. The IAC group was also significantly
more likely to demonstrate a tumor response as evalu-
ated with the modified RECIST guidelines described in
this study.
The IAC administration procedure is technically chal-
lenging, and requires a strong understanding of the vas-
cular anatomy. Additionally, as the arterial system is
being accessed, it is important to be cognizant of the
placement of instrumentation and the potential loss of
blood that can occur with these arterial procedures.
Similar chemotherapy safety protocols to what are uti-
lized for IVC administration should be instituted for
IAC administration, and all members of the treatment
team should take proper precautions. Complications
that can be specific to the IAC cases such as anesthetic
complications (eg, reaction to anesthetic drugs, aspira-
tion pneumonia), excessive blood loss, a lack of techni-
cal success (inability to access the blood supply or
administer chemotherapy), or embolization/thrombosis
after treatment were not encountered in these cases.
Although the IAC technique requires general anesthesia
and therefore associated potential risks, these did not
appear to contribute to complications in this study. In
addition, the procedure times were of relatively short
duration.
As arterial cannulation is performed, it is important
to consider the means of closure of the arterial site.
Options for closure in dogs include ligation of the
artery, vascular repair, manual pressure after the proce-
dure, or vascular closure devices. Because of expense,
vascular closure devices are not often utilized in clinical
canine cases; additionally, these devices are generally not
recommended for closure of carotid artery sites. Liga-
tion of the artery was chosen in this study as this tends
to be well-tolerated in the dog as a result of abundant
collateral circulation.25,26 Femoral artery access sites
were chosen fairly distal in the groin to permit subse-
quent access to the same femoral artery for potential
future interventions. The collateral vasculature associ-
ated with the femoral artery of dogs helps maintain
blood flow and limits thrombosis in most cases; the
authors have accessed a single femoral artery up to 4
times in dogs. In the one case that underwent bilateral
common carotid artery ligation, after ligation neurologic
dysfunction was noted. The bilateral ligation of the com-
mon carotid arteries has been demonstrated experimen-
tally to be tolerable in dogs.25,26 However, based on the
results in this one case, the recommendation of perform-
ing IAC while utilizing the common carotid artery bilat-
erally needs to be cautiously undertaken in dogs.
Major complications secondary to chemotherapy
administration were not noted in the IAC group. A
proposed advantage of IAC over IVC is the lower
potential adverse effects associated with chemother-
apy.20 Research in laboratory rabbits with bladder
tumors determined that internal iliac artery infusion of
carboplatin and pirarubicin was safely tolerated and
resulted in significantly higher chemotherapy levels
within the bladder tumor itself.27 In addition, all tumors
receiving intraarterial treatment reduced in size with
37.5% disappearing compared to those receiving intra-
venous treatment in which all tumors grew in size.27
The improved efficacy of intraarterial drug delivery is
thought to result from the initial increased drug concen-
tration in the tumor after intraarterial administration.
Higher local chemotherapy concentrations would trans-
late into lower systemic chemotherapy exposures and
possibly reduced systemic adverse events. Another study
in laboratory dogs receiving internal iliac artery infu-
sion of pirarubicin demonstrated tolerability and the
bladder mucosa and muscle concentrations of chemo-
therapy were 8 times higher than that of dogs receiving
IVC. In addition, the perivesical adipose tissues, pelvic
lymph nodes and prostate all had significantly higher
tissue levels when compared with intravenous adminis-
tration.28 The increased drug level in the regional tissues
and lymph nodes might in fact be an additional advan-
tage with this approach since multifocal vesical implant
metastasis, prostatic involvement, and regional lymph
node metastasis are common sites of tumor progression
in dogs with lower urinary tract tumors.
The authors chose to utilize the NSAID meloxicam
because of its readily available injectable formulation as
well as the literature suggesting antitumor activity in
laboratory tumor models with a wide range of various
types of carcinomas and sarcomas.29,30 There are no
published reports of the use of meloxicam in canine
TCC, to the authors’ knowledge, however, the results
from in-vitro as well as in-vivo mice tumor models are
promising.29,30 As other studies have confirmed the effi-
cacy of piroxicam and deracoxib4,16,17, it is important
to consider that many NSAIDs might have antitumor
properties, but there is still much to be elucidated about
what NSAID (if any) could be considered the treat-
ment-of-choice. Furthermore, the intravenous adminis-
tration of NSAIDs has been shown to result in higher
plasma concentrations and extravascular penetration
when compared to oral administration.31 It remains
unclear if the use of different NSAIDs in the IVC cases
or the use of NSAIDs administered PO versus intraarte-
rially in this report led to the comparatively worse
tumor response rates.
Ultrasonography was used to assess the initial tumor
response to the evaluated therapies because of the non-
invasive nature and easy accessibility to this diagnostic
modality. Additionally, many clinics utilize ultrasonog-
raphy to monitor tumor response to chemotherapeutics
and for the presence of recurrence or further dissemina-
tion. It should be considered, however, that the evalua-
tion of lower urinary tract neoplasia size can be highly
variable when evaluated with ultrasonography and has
been shown to be affected by the operator as well as the
volume of the bladder.32 Additionally, the tumors var-
ied in size, and it is possible that it might be difficult to
obtain an accurate measurement of a small tumor as
compared to a large tumor. As the cases were evaluated
retrospectively, images were not obtained uniformly as
a specific protocol for image acquisition was not utilized
and different radiologists acquired the images originally.
The RECIST criteria referenced in this study exclude
the use of ultrasonography for tumor response evaluation
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because of these inherent limitations; however, ultraso-
nography was still used in this project because of its clini-
cal relevance for management of these tumors in dogs.
Recently, the use of 3-D ultrasonography demonstrated
high accuracy in determining tumor volume when com-
pared to CT, which was considered the preferred refer-
ence method.33 In many clinics, anesthesia is utilized to
perform CT and MRI in dogs potentially preventing
those imaging modalities from being used regularly in a
clinical setting to monitor tumor size and response to
therapy; however this might be less limiting if the patient
will already be under general anesthesia for IAC adminis-
tration.
There are several limitations of this study that should
be discussed. The study was performed retrospectively
and descriptively, and required data recording from
medical records. This process is always associated with
inherent inaccuracies, and the potential for incorrectly
recorded data or loss of information exists. This study
only evaluated the initial tumor response as the before
treatment ultrasonography measurements were only
compared to the first after treatment measurements.
These results are short-term, and a more uniform
assessment involving more time points as well as long-
term and final outcome should be performed. One of
the potentially more significant limitations is in regards
to ultrasonographic tumor measurements. Although a
single radiologist reviewed all studies and performed
her own measurements on each case, the radiologist
was still limited to reviewing images obtained by the ini-
tial radiologists. Additionally, not every radiologist
obtained images in transverse as well as sagittal imaging
planes, nor did every case have cine video loops (which
could make the reviewing process more “real time”).
Also, it is standard at our institutions that when a radi-
ologist is reevaluating a patient, previously obtained
ultrasound images will be reviewed in an effort to
obtain images and measurements in a very similar
plane, to minimize the inherent operator dependent dif-
ferences in tumor assessment; this results in the radiolo-
gist’s ability to perform follow-up measurements in
imaging planes similar to those used in the original
study. It is also noteworthy that some of the static
images had measurements recorded by the attending
radiologist and the measurements obtained in retrospect
by the reviewing radiologist were consistent with that
obtained originally.
There are a few limitations of performing this proce-
dure specifically. As stated above, only individuals who
have significant experience with interventional proce-
dures and instrumentation should perform these IAC
procedures. The NSAID administration was not stan-
dardized in the IVC group, and cases in the IAC group
that received meloxicam only were compared to cases in
the IVC group that received various NSAIDs; further,
dogs in the IVC group received oral NSAIDs while
dogs in the IAC group received intraarterial NSAIDs.
The clinical consequences of this variation cannot be
interpreted. Additionally, the procedure requires sacri-
fice of an artery if vascular ligation is elected. Although
this is generally well-tolerated, this might decrease the
number of times that a vessel can be accessed thus lim-
iting the number of possible treatments. Lastly, the pro-
cedure requires anesthesia, which always poses inherent
risks.
Several future studies should be considered based on
the results of this initial study. Although the initial
response to the combination of carboplatin and meloxi-
cam is encouraging, other chemotherapeutics can be
evaluated. Ideally, a prospective, randomized trial
would be conducted that can evaluate a chemotherapy
protocol that is the same for both IA and IV adminis-
tration. Current work includes the evaluation of sys-
temic drug levels after chemotherapy administered via
the intraarterial and intravenous routes, and additional
correlation with the development of adverse events
could be made. Lastly, future studies might employ the
use of other imaging diagnostics to assess the tumor
response in a way that might be more reliable then
ultrasonography alone; while the clinical application of
this might be limited, these assessments could provide a
guideline for future therapeutics.
In conclusion, this study demonstrated successful
IAC administration in a cohort of dogs with lower uri-
nary tract neoplasia. Additionally, a significantly greater
reduction in tumor size (longest unidimensional mea-
surement) was noted when comparing IAC to IVC,
although the follow-up time was short and the impact
on long-term outcome and survival was not determined.
Further investigation is necessary to determine the
potential for regular application of this technique in the
treatment of canine lower urinary tract neoplasia and
other solid tumors with poor response to systemically
administered chemotherapy.
Footnotes
a PDS, Ethicon Inc, Somerville, NJ
b Veni-Systems Clear Cath, Abbott Laboratories, Sligo, Ireland
c Weasel wire, Infiniti Medical LLC, Menlo Park, CA
d Introducer Sheath, Infiniti Medical LLC, Menlo Park, CA
e Berenstein Catheter, Infiniti Medical LLC, Menlo Park, CA
f Omnipaque 240 (iohexol), GE Healthcare Inc, Princeton, NJ
g Cobra Catheter, Infiniti Medical LLC, Menlo Park, CA
h Simmons Catheter, Infiniti Medical LLC, Menlo Park, CA
i Microwire, Infiniti Medical LLC, Menlo Park, CA
j Microcatheter, Infiniti Medical LLC, Menlo Park, CA
k Monocryl, Ethicon Inc, Somerville, NJ
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